TrimTabs-国际自由现金流优质主动型ETF TTAI 深 沪
已收盘 12-12 16:00:00 美东时间
29.99
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 29.99
- 总市值 5998.00万
- 52周最高 30.8479
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 27.0854
- 委 比 0.00%
- 总股本 200.00万
- 历史最高 32.8183
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.1154
- 每 手 1
- 风险率 1.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength.
今天 02:06
Market-Moving News for August 7th
LLY: -14% | Eli Lilly and Company shares are trading lower after the company announced topline results from the Phase 3 ATTAIN-1 trial evaluating orforglipron in adults with obesity. VKTX: 15% | Viking
08-07 19:17
Eli Lilly and Company shares are trading lower after the company announced topline results from the Phase 3 ATTAIN-1 trial evaluating orforglipron in adults with obesity.
Eli Lilly and Company shares are trading lower after the company announced topl...
08-07 18:28
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.
07-10 02:55
礼来(LLY.US)公布口服减肥药orforglipron三期临床数据：最高剂量下40周减重8%!
礼来于上周六公布了其口服小分子GLP-1类药物orforglipron在三期临床试验ACHIEVE-1中的详细数据。
06-23 14:23
Why did Lilly data for oral GLP-1 boost Structure and Metsera?
Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli Lilly (NYSE:LLY) on Thursday after the Indiana-based pharma giant reported Pha...
04-18 02:24
Eli Lilly prelaunch inventory raises hopes for upcoming weight loss pill
Eli Lilly (NYSE:LLY) has raised expectations for its experimental weight loss pill, orforglipron, capitalizing $548.1M in pre-launch inventory in 2024 for the next-gen drug ahead of a potential regula...
02-21 02:53
全球药企的减肥梦
由GLP-1引爆的减肥药赛道进入白热化竞争阶段。海外两大巨头诺和诺德、礼来分庭抗礼，国内信达进度领先，恒瑞、华东医药、石药集团、豪森和中国生物制药等纷纷下注。...
2023-12-05 11:20
减肥市场风云——从临床数据看减肥药争奇斗艳
医药魔方 制药企业们“挤破头”抢滩减肥赛道，至于谁能主宰这片战场，要论先机，更取决于产品本身质素。在安全可控的前提下出色的减肥效果是终极必杀技...
2023-11-04 10:32
